Rituximab for minimal change disease in adults: Long-term follow-up

Nephrology Dialysis Transplantation

Volumn 29, Issue 4, 2014, Pages 851-856

  Bruchfeld, Annette ^a   Benedek, Samiha ^a   Hilderman, Marie ^a   Medin, Charlotte ^a   Snaedal Jonsdottir, Sunna ^a   Korkeila, Maarit ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

B cell depletion; glucocorticoid sparing; long term outcome; minimal change disease; relapse; rituximab; safety

Indexed keywords

ALENDRONIC ACID; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ATORVASTATIN; CALCIUM; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE SODIUM SUCCINATE; INSULIN; LEVAMISOLE; METHYLPREDNISOLONE; OMEPRAZOLE; PARACETAMOL; PREDNISOLONE; RITUXIMAB; SIMVASTATIN; TACROLIMUS; VITAMIN D; WARFARIN;

ABDOMINAL WALL HERNIA; ABSENCE OF SIDE EFFECTS; ACHILLES TENDON RUPTURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY MENOPAUSE; EYE REDNESS; FEMALE; FOLLOW UP; FRACTURE; GLUCOSE INTOLERANCE; HUMAN; HUMAN TISSUE; HYPOTENSION; INSOMNIA; KIDNEY BIOPSY; KIDNEY DISEASE; LONG TERM CARE; LYMPHOCYTE DEPLETION; MALE; MINIMAL CHANGE DISEASE; MOOD DISORDER; MORBID OBESITY; MYALGIA; NAUSEA; OCULAR PRURITUS; OSTEOPOROSIS; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

B-CELL DEPLETION; GLUCOCORTICOID SPARING; LONG-TERM OUTCOME; MINIMAL CHANGE DISEASE; RELAPSE; RITUXIMAB; SAFETY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; BIOPSY; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; MIDDLE AGED; NEPHROSIS, LIPOID; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897452958     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft312     Document Type: Article

References (27)

1. Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 1981; 20: 765-771
2. Cameron JS. Nephrotic syndrome in the elderly. Semin Nephrol 1996; 16: 319-329
3. Waldman M, Crew RJ, Valeri A et al. Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2: 445-453
4. Shalhoub RJ. Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 1974; 2: 556-560
5. Lai KW, Wei CL, Tan LK et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 2007; 18: 1476-1485
6. Yap HK, CheungW, Murugasu B et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: Evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999; 10: 529-537
7. Sellier-Leclerc AL, Duval A, Riveron S et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol 2007; 18: 2732-2739
8. Garin EH, Diaz LN, Mu W et al. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 2009; 20: 260-266 (Kidney Int. 2010 Aug;78(3):296-302
9. Garin EH, Mu W, Arthur JM et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 2010; 78: 296-302
10. Bargman JM. Management of minimal lesion glomerulonephritis: Evidencebased recommendations. Kidney Int Suppl 1999; 70: S3-16
11. Jayne D. Role of Rituximab Therapy in Glomerulonephritis. J Am Soc Nephrol 2010; 21: 14-17
12. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis. N Engl J Med. 2010; 363: 211-220
13. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-Associated vasculitis. N Engl J Med 2010; 363: 221-232
14. Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 2006; 21: 1698-1700
15. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroidresistant nephrotic syndrome. N Engl J Med 2007; 356: 2751-2752
16. Kemper MJ, Gellermann J, Habbig S et al. Long-Term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 1910-1915
17. Francois H, Daugas E, Bensman A et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: First case report and pathophysiological considerations. Am J Kidney Dis 2007; 49: 158-161
18. Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol 2011; 76: 151-158
19. Takei T, Itabashi M, Moriyama T et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant 2013; 28: 1225-1232
20. Bruchfeld A, Benedek S, Hilderman M et al. Rituximab for multirelapsing, steroid-dependent or steroid-resistant, minimal-change nephropathy-A report of nine adult cases. Nephrol Rev 2010; 2: 6-9 DOI: 10.4081/nr.2010.e2
21. Munyentwali H, Bouachi K, Audard V et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013; 83: 511-516
22. Guigonis V, Dallocchio A, Baudouin V et al. Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: A multicentric series of 22 cases. Pediatr Nephrol 2008; 23: 1269-1279
23. Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum 2012; 64: 3760-3769
24. van Vollenhoven RF, Emery P, Bingham CO, III et al. Long-Term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2012 [Epub ahead of print]
25. Kemper MJ, Meyer-Jark T, Lilova M et al. Combined T-And B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 2003; 60: 242-247
26. Stasi R, Cooper N, Del Poeta G et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008; 112: 1147-1150
27. Weiner GJ. Rituximab: Mechanism of action. Semin Hematol 2010; 47: 115-123